GleamWall
中文EN

OTLC Oncotelic Therapeutics, Inc.

Pharmaceutical Preparations · OTC · SEC CIK 908259 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY14,923.8%
TTM EPS YoY—
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE181.6%
ROA117.3%
ROIC (approx.)-3.2%
Asset turnover—

Leverage & solvency

Liabilities / assets33.4%
Debt / equity0.00x
Current ratio0.07x
Interest coverage—

Cash quality & payout

Operating cash flow / net income-0.01x
Accruals ratio118.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue——
R&D expense$4,357—
SG&A expense$3.18M$376,013
Operating income-$3.19M-$3.58M
Pretax income$360.57M-$4.78M
Income tax$111.55M—
Net income$249.28M-$4.52M
EPS (basic)0.590.01
EPS (diluted)0.59-0.01
Weighted avg. shares (diluted)422.23M404.40M
Balance sheet
Cash & equivalents$88,857$86,128
Receivables$51,324$18,976
Current assets$1.20M$134,211
Goodwill$2.79M$2.79M
Total assets$393.09M$26.68M
Current liabilities$18.14M$19.20M
Short-term debt—$2.42M
Total liabilities$131.36M$19.20M
Shareholders' equity$262.76M$8.25M
Shares outstanding442.60M407.29M
Cash flow statement
Operating cash flow-$1.38M-$740,277
Financing cash flow$1.39M$656,000
Stock-based compensation$2.38M$0

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.